The dopamine D4 receptors and mechanisms of antipsychotic atypicality

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 7, 2003, Pages 1091-1099

  Wong, Albert H C ^b   Van Tol, Hubert H M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

Antipsychotics; Attention; Cognition; Dopamine D4 receptor; Genetics; Molecular; Schizophrenia; Signaling

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 4 RECEPTOR; FANANSERIN; HALOPERIDOL; NDG 96 1; NEUROLEPTIC AGENT; PNU 101387 G; RACLOPRIDE; RECEPTOR SUBTYPE; SULPIRIDE; UNCLASSIFIED DRUG; DOPAMINE 2 RECEPTOR; DRD4 PROTEIN, HUMAN;

ATTENTION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; GENE DELETION; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PHENOTYPE; RECEPTOR AFFINITY; RECEPTOR GENE; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECT; GENETICS; METABOLISM; NEUROPHYSIOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; NEUROPHYSIOLOGY; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SIGNAL TRANSDUCTION;

EID: 0345690099     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.09.005     Document Type: Article

References (77)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry. 155:1998;761-767.
2. 4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys. Neuropsychopharmacology. 23:2000;405-410.
3. 4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol. Pharmacol. 46:1994;364-373.
4. 4 receptor variants. J. Neurochem. 65:1995;1157-1165.
5. 2 receptors. Nature. 377:1995;424-428.
6. Barkley R.A. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol. Bull. 121:1997;65-94.
7. Barkley R.A., Grodzinsky G., DuPaul G.J. Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report. J. Abnorm. Child Psychol. 20:1992;163-188.
8. 4 receptor gene. J. Am. Acad. Child Adolesc. Psychiatry. 40:2001;118-121.
9. 4 dopamine and metabotropic glutamate receptors in cerebral cortex and striatum in rat brain. Neurochem. Res. 26:2001;345-352.
10. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA. 94:1997;2569-2574.
11. 4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. J. Neural. Transm. 105:1998;749-767.
12. 4 receptor locus. Hum. Genet. 98:1996;91-101.
13. 4 receptors coupled to adenylate cyclase. Proc. Natl. Acad. Sci. USA. 89:1992;12093-12097.
14. Evaluating the effects of antipsychotics on cognition in schizophrenia. J. Clin. Psychiatry. 59(Suppl. 12):1998;35-40.
15. 4 receptor in the mouse brain. J. Neurosci. Res. 59:2000;202-208.
16. 4 gene locus. Proc. Natl. Acad. Sci. USA. 99:2002;309-314.
17. 4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 19:1999;9550-9556.
18. 4 receptors results in enhanced reactivity to unconditioned, but not conditioned, fear. Eur. J. Neurosci. 15:2002;158-164.
19. 4 receptor gene and attention deficit hyperactivity disorder. Am. J. Psychiatry. 158:2001;1052-1057.
20. 4.4 receptor. Br. J. Pharmacol. 124:1998;889-896.
21. 4.4 receptors expressed in CHO cells. Br. J. Pharmacol. 128:1999;613-620.
22. 4 exon III repetitive region in several species of the order Carnivora. J. Vet. Med. Sci. 64:2002;747-749.
23. 4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology (Berl.). 142:1999;78-84.
24. 4.10 receptor variants. Pharmacogenetics. 9:1999;561-568.
25. 4 dopamine receptor variants with Giα subtypes. Biochemistry. 39:2000;3734-3744.
26. Kelly M.A., Rubinstein M., Phillips T.J., Lessov C.N., Burkhart-Kasch S., Zhang G., Bunzow J.R., Fang Y., Gerhardt G.A., Grandy D.K., Low M.J. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J. Neurosci. 18:1998;3470-3479.
27. 2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron. 35:2002;1111-1122.
28. 4 Dopamine Antagonist Group. Arch. Gen. Psychiatry. 54:1997;567-572.
29. 4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry. 1:1996;121-124.
30. 4 receptor in the primate brain with positron emission tomography. Nucl. Med. Biol. 27:2000;707-714.
31. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA. 93:1996;9235-9240.
32. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37:1999;1-11.
33. Lei S., Lu W.Y., Xiong Z.G., Orser B.A., Valenzuela C.F., MacDonald J.F. Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons. J. Biol. Chem. 274:1999;30617-30623.
34. 4 (DRD4) gene. Hum. Mol. Genet. 2:1993;767-773.
35. 4valine194glycine, is insensitive to dopamine and clozapine: report of a homozygous individual. Am. J. Med. Genet. 61:1996;277-282.
36. 4 receptor (DRD4) gene sequence within and among nonhuman primate species. Proc. Natl. Acad. Sci. USA. 92:1995;427-431.
37. Luthman J., Fredriksson A., Lewander T., Jonsson G., Archer T. Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. Psychopharmacology (Berl.). 99:1989;550-557.
38. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-255.
39. 4 receptors in GABAergic neurons of the primate brain. Nature. 381:1996;245-248.
40. 4 dopamine receptor polymorphic region in two dog breeds, Golden retriever and Shiba. J. Vet. Med. Sci. 61:1999;1281-1286.
41. 4 gene in dogs. J. Hered. 92:2001;433-436.
42. 4 receptors. J. Neurosci. 22:2002;2063-2073.
43. 4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum. Mol. Genet. 3:1994;2207-2212.
44. 4 receptor: one decade of research. Eur. J. Pharmacol. 405:2000;303-327.
45. 2L receptor stimulation of the mitogen-activated protein kinase pathway is dependent on trans-activation of the platelet-derived growth factor receptor. Mol. Pharmacol. 60:2001;92-103.
46. Okuyama Y., Ishiguro H., Nankai M., Shibuya H., Watanabe A., Arinami T. Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol. Psychiatry. 5:2000;64-69.
47. 4 receptor. Biochemistry. 37:1998;15726-15736.
48. 4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol. 4:1992;137-146.
49. Otmakhova N.A., Lisman J.E. Dopamine selectively inhibits the direct cortical pathway to the CA1 hippocampal region. J. Neurosci. 19:1999;1437-1445.
50. 4 receptor activation inhibits presynaptically glutamatergic neurotransmission in the rat supraoptic nucleus. J. Neurophysiol. 86:2001;1149-1155.
51. 4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J. Neurosci. 19:1999;4627-4633.
52. 4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J. Neurochem. 80:2002;219-229.
53. 4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell. 90:1997;991-1001.
54. 4 receptor-deficient mice display cortical hyperexcitability. J. Neurosci. 21:2001;3756-3763.
55. 4 receptor gene (DRD4). Am. J. Med. Genet. 88:1999;705-709.
56. 4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. Am. J. Med. Genet. 54:1994;384-390.
57. 3H]benzquinoline. Synapse. 25:1997;137-146.
58. Shaywitz B.A., Yager R.D., Klopper J.H. Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction. Science. 191:1976;305-308.
59. Shaywitz B.A., Klopper J.H., Yager R.D., Gordon J.W. Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine. Nature. 261:1976;153-155.
60. 4 receptor antagonist L-750,667 in nonhuman primate brain. Nucl. Med. Biol. 27:2000;547-556.
61. 4 receptor localization in the rat nucleus accumbens shell. Synapse. 36:2000;222-232.
62. 2A antagonist fananserin in the treatment of schizophrenia. Am. J. Psychiatry. 156:1999;419-425.
63. Valenzuela C.F., Xiong Z., MacDonald J.F., Weiner J.L., Frazier C.J., Dunwiddie T.V., Kazlauskas A., Whiting P.J., Harris R.A. Platelet-derived growth factor induces a long-term inhibition of N-methyl-D-aspartate receptor function. J. Biol. Chem. 271:1996;16151-16159.
64. Valenzuela C.F., Kazlauskas A., Weiner J.L. Roles of platelet-derived growth factor in the developing and mature nervous systems. Brain Res. Brain Res. Rev. 24:1997;77-89.
65. 4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
66. 4 receptor variants in the human population. Nature. 358:1992;149-152.
67. Waddington J.L., Clifford J.J., McNamara F.N., Tomiyama K., Koshikawa N., Croke D.T. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;925-964.
68. 4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. J. Neurosci. 22:2002;9185-9193.
69. 4 receptors in the rat brain- immunocytochemical study. J. Physiol. Pharmacol. 51:2000;205-221.
70. 4 receptor ligands: relation to antipsychotic action. Eur. J. Pharmacol. 351:1998;273-286.
71. Wong A.H., Buckle C.E., Van Tol H.H.M. Polymorphisms in dopamine receptors: what do they tell us? Eur. J. Pharmacol. 410:2000;183-203.
72. 4 dopamine receptor couples to cone transducin (Gαt2) to inhibit forskolin-stimulated cAMP accumulation. J. Biol. Chem. 272:1997;16599-16602.
73. 4 receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. Neuropsychopharmacology. 25:2001;624-632.
74. 4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. Psychopharmacology (Berl.). 161:2002;100-106.
75. 4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning. Neuropsychopharmacology. 26:2002;625-633.
76. 4 MN9D cells. Mol. Pharmacol. 60:2001;857-864.
77. Zhou Q.Y., Palmiter R.D. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell. 83:1995;1197-1209.